has previously been shown in a preliminary study to be significantly lower in patients with CRF than in controls.' Since the HbA, content of any erythrocyte is dependent on the dura-
jects. Concentrations of HbA, in patients on haemodialysis, peritoneal dialysis, and those with steady state CRF prior to dialysis were not significantly different from each other. Whereas patients with successful renal transplants of greater than 3 months' duration had HbA, concentrations indistinguishable from controls, HbA, in patients with transplants of shorter duration were significantly lower. These observations are suggestive of a shortened erythrocyte survival in CRF per se. Furthermore, these results indicate: (a) the inadequacy of HbA, in monitoring the quality of diabetic control in patients with CRF, and (b) the absence of a specific effect of dialysis on HbAI, and the restoration to normal of HbA, after successful renal transplantation.
Haemoglobin A, (HbA,) has previously been shown in a preliminary study to be significantly lower in patients with CRF than in controls.' Since the HbA, content of any erythrocyte is dependent on the duration of glycosylation-that is, life span of the erythrocyte and the rate of glycosylation-that is, the concentration of plasma glucose,2 it follows that a diminu- Group 2 Patients (n = 10) with CRF (Cr cl < 10 ml/min) on peritoneal dialysis for duration of more than 1 month (mean plasma glucose = 4*6 mmol/1).
Group 3 Patients (n = 19) with CRF (age range 10 to 53 years, mean 34 years) on long-term haemodialysis for duration of more than 2 months'
(mean plasma glucose = 4-0 mmol/1).
Group 4 Patients (n = 6) with recent renal transplants less than 3 months' duration (Cr cl 10 to 53 ml/min) (mean plasma glucose = 4.5 mmol/l).
Group 5 Patients (n = 20) with successful renal transplants greater than 3 months' duration (Cr cl 25 to 120 ml/min) (mean plasma glucose = 3.9 mmoIl).
Group 6 Control group (n = 17) (mean plasma glucose 4-2 mmol/l).
None of these patients had fasting or post prandial hypoglycaemia, hyperglycaemia, glycosuria or hypoglycaemia.
Blood samples were collected in heparin and were stored in a refrigerator at 4°C before HbA, measure- In patients with transplants of less than 3 months' duration HbA1% (mean + SD = 5-7 + 0.7) was similar to that in patients with CRF and was significantly lower than that in controls (p < 0.01). HbA,% in patients with successful renal transplants of longer duration (mean + SD = 6-8 1-0) was significantly greater than that in patients with CRF (p < 0-01) and those with recent transplants (p < 0-01); it was not significantly different from that in controls. There was a significant correlation between blood glucose concentration and HbAI% in patients on haemodialysis (r = 0-8), those with long term transplants (r = 0-8) and in controls (r = 0-65) (Fig.   2 ). Patients on long-term haemodialysis had lower HbA, % for a given blood glucose concentration that when compared with normal subjects and there was no overlap between the two groups (p < 0-05, Student's unpaired t test). However, it is surprising that HbA,% in patients on haemodialysis was not significantly different either from that in uraemic patients prior to dialysis or that in patients on peritoneal dialysis. This suggests that the main cause of shortened RBC survival in patients with CRF is uraemia and not haemodialysis.
In conclusion, CRF is associated with a reduction of HbA, irrespective of dialysis treatment or its mode.
This reduction in HbA, is restored to normal after successful renal transplantation. These observations may have important implications in terms of erythrocyte survival and the assessment of glycaemic control in CRF.
